Biomedical subjects

Peter Grimm

Publications and source records attributed to Peter Grimm.

3 recordsLinked to original sources

PubMed2005

Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.

PURPOSE: To conduct a multi-institutional comparison of prostate brachytherapy pre-implant dosimetry of Pd-103 and I-125. METHODS AND MATERIALS: Eight experienced brachytherapists submitted Pd-103 and I-125 monotherapeutic and boost pre-implant dosimetry plans for central review. All 32 plans were calculated using the same transrectal ultrasound volumetric study. Seeds of any strength were acceptable, but were restricted to Theraseed Model 200 (Theragenics Inc., Buford, GA) and Oncura Oncoseed Model 6711 (Oncura, Plymouth Meeting, PA). The dosimetric analysis included evaluation of target volume, target to prostate ratio, target length, number of needles, seed activity, number of seeds, total activity, total activity divided by treatment planning volume, the use of extracapsular seeds, and average treatment margins (defined as the perpendicular distance between the prostate capsule and the 100% isodose line). Prostate coverage was defined in terms of V(100)/V(150)/V(200)/V(300) and D(100)/D(90)/D(50), whereas urethral dosimetry consisted of UV(100)/UV(150)/UV(200) and UD(90)/UD(50). RESULTS: The mean planning target volume to prostate volume ratio varied dramatically (mean 1.29, range 0.99-1.76) with the target length ranging from 3.5 to 4.5 cm. Although the prostate V(100) was >95% in all cases, the V(150) ranged from 29.9% to 92.1% and the V(200) from 6.72% to 52.5%. The urethral V(100) was 100% in all cases with six of the eight brachytherapists limiting the UV(150) to <3%. However, the median urethral dose varied by up to 50%. Treatment margins also varied significantly (average 3.98 mm, range 0.32-7.68 mm). All brachytherapists used extracapsular seeds with five implanting >25% of the seeds in extracapsular locations (range 6.4-58.2%). In addition, significant variability existed in the number of needles, number of seeds, and seed strength. CONCLUSIONS: This study highlights the substantial variability that exists regarding target volume, seed strength, dose homogeneity, treatment margins, and extracapsular seed placement, although prostate brachytherapy prescription doses are uniform. The standardization of pre-implant dosimetry is essential for meaningful multi-institutional comparisons of biochemical outcomes and morbidity.

Brachytherapy↗

PubMed2004

Advances in brachytherapy.

During the past 15 years, permanent seed brachytherapy for prostate cancer has advanced significantly in all areas, including patient selection, treatment planning, technique, and technology (eg, seeds stranded in Vicryl suture). These improvements have made transperineal seed implantation an accurate and practical treatment option for men with low-, intermediate-, and high-risk disease. Because of the evidence that the various treatment options for prostate cancer are likely to be equally successful in terms of long-term cancer control, continuing efforts focus on enhancing the quality of life of implant patients.

Journal Article↗

PubMed2003

Interpretation of pre- versus postimplant TRUS images.

In order to summarize the inter-observer variability of pre- and postimplant TRUS image interpretation. Ten patients treated with Pd-103 brachytherapy were studied. Preimplant prostatevolumes ranged from 21 to 51 cm3. The number of sources implanted ranged from 74 to 155, and the number of sources per cm3 prostate volume ranged from 3.0 to 4.3. A set of transverse images (6 MHz) were taken immediately prior to and following source placement. Original printer images were sent to four investigators and the prostate outlined independently on a cellophane overlay. The overlays were digitized into a Varian MMS 7.0 treatment planning system (Charlottesville, VA) for volume determinations. There was moderate interobserver variability in TRUS volume determination, accentuated for the postimplant images. The standard deviations varied from 2% to 13% of the mean (median: 7%) for preimplant volumes, versus 7% to 32% (median: 13%) for postimplant volumes. Interobserver prostatic edge (border) localization variability was greatest at the base and apex, with closer agreement along the posterior border. For preimplant images, the majority of edge points were within 1.0 mm of the mean. At each coordinate, with the exception of the anterior base, the majority of points were within 2.0 mm of the mean. In general, border identification variability was greater in the post implant images. While all prostate imaging modalities suffer from interobserver variability, preimplant and postimplant TRUS appears capable of consistently determining prostatic volume and borders. It appears that intraoperative TRUS-based dosimetry is a practical goal, provided that seed location coordinates can be added to the prostatic edge information derived from TRUS images.

Brachytherapy↗